Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 299

1.

Photoaffinity labeling of P450Cam by an imidazole-tethered benzophenone probe.

Trnka MJ, Doneanu CE, Trager WF.

Arch Biochem Biophys. 2006 Jan 1;445(1):95-107. Epub 2005 Nov 14.

PMID:
16321358
2.

Human malaria parasites in continuous culture. 1976.

Trager W, Jensen JB.

J Parasitol. 2005 Jun;91(3):484-6. No abstract available.

PMID:
16108535
3.

What triggers the gametocyte pathway in Plasmodium falciparum?

Trager W.

Trends Parasitol. 2005 Jun;21(6):262-4. No abstract available.

PMID:
15922244
4.

Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors.

Suzuki H, Kneller MB, Rock DA, Jones JP, Trager WF, Rettie AE.

Arch Biochem Biophys. 2004 Sep 1;429(1):1-15.

PMID:
15288804
6.

The formation of haemozoin--further intrigue.

Trager W.

Trends Parasitol. 2003 Sep;19(9):388. No abstract available.

PMID:
12957513
7.

Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition.

Neal JM, Kunze KL, Levy RH, O'Reilly RA, Trager WF.

Drug Metab Dispos. 2003 Aug;31(8):1043-8.

PMID:
12867493
8.

Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.

Yao C, Kunze KL, Trager WF, Kharasch ED, Levy RH.

Drug Metab Dispos. 2003 May;31(5):565-71.

PMID:
12695344
9.

Characterization of covalent adducts to intact cytochrome P450s by mass spectrometry.

Lightning LK, Trager WF.

Methods Enzymol. 2002;357:296-300. No abstract available.

PMID:
12424919
10.

Loose ends: axenic culture, parasitophorous vacuoles, bird malaria.

Trager W.

Parassitologia. 2002 Jun;44(1-2):117-21. Review.

PMID:
12404819
11.

Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.

Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, Mather GG, Roskos LK, Shen DD, Thummel KE, Trager WF, Curtin CR, Doose DR, Gisclon LG, Bialer M.

Epilepsia. 2002 Jul;43(7):691-6. Erratum in: Epilepsia 2002 Oct;43(10):1273.

12.

(+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19.

Suzuki H, Kneller MB, Haining RL, Trager WF, Rettie AE.

Drug Metab Dispos. 2002 Mar;30(3):235-9.

PMID:
11854139
13.

On the release of malaria merozoites.

Trager W.

Trends Parasitol. 2002 Feb;18(2):60-1. No abstract available.

PMID:
11832292
14.

Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.

Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I, Levy RH.

Clin Pharmacol Ther. 2001 Nov;70(5):415-24.

PMID:
11719727
15.

Active site characteristics of CYP4B1 probed with aromatic ligands.

Henne KR, Fisher MB, Iyer KR, Lang DH, Trager WF, Rettie AE.

Biochemistry. 2001 Jul 24;40(29):8597-605.

PMID:
11456500
16.

Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s.

He M, Rettie AE, Neal J, Trager WF.

Drug Metab Dispos. 2001 May;29(5):701-11.

PMID:
11302937
17.

A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.

Rao S, Aoyama R, Schrag M, Trager WF, Rettie A, Jones JP.

J Med Chem. 2000 Jul 27;43(15):2789-96.

PMID:
10956186
18.

Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394.

Lightning LK, Jones JP, Friedberg T, Pritchard MP, Shou M, Rushmore TH, Trager WF.

Biochemistry. 2000 Apr 18;39(15):4276-87.

PMID:
10757976
19.

Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.

Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ.

Drug Metab Dispos. 1999 Dec;27(12):1488-95.

PMID:
10570031
20.

Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.

He M, Korzekwa KR, Jones JP, Rettie AE, Trager WF.

Arch Biochem Biophys. 1999 Dec 1;372(1):16-28.

PMID:
10562412
21.

Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.

Haining RL, Jones JP, Henne KR, Fisher MB, Koop DR, Trager WF, Rettie AE.

Biochemistry. 1999 Mar 16;38(11):3285-92.

PMID:
10079071
22.

Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9.

Koenigs LL, Peter RM, Hunter AP, Haining RL, Rettie AE, Friedberg T, Pritchard MP, Shou M, Rushmore TH, Trager WF.

Biochemistry. 1999 Feb 23;38(8):2312-9.

PMID:
10029524
23.

Plasmodium falciparum: enhanced gametocyte formation in vitro in reticulocyte-rich blood.

Trager W, Gill GS, Lawrence C, Nagel RL.

Exp Parasitol. 1999 Feb;91(2):115-8.

PMID:
9990338
24.

In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent.

Nicolas JM, Collart P, Gerin B, Mather G, Trager W, Levy R, Roba J.

Drug Metab Dispos. 1999 Feb;27(2):250-4.

PMID:
9929511
25.
26.

Mechanism-based inactivation of P450 2A6 by furanocoumarins.

Koenigs LL, Trager WF.

Biochemistry. 1998 Jul 14;37(28):10047-61.

PMID:
9665710
27.

(R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6.

Khojasteh-Bakht SC, Koenigs LL, Peter RM, Trager WF, Nelson SD.

Drug Metab Dispos. 1998 Jul;26(7):701-4.

PMID:
9660853
28.

Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6.

Chen W, Koenigs LL, Thompson SJ, Peter RM, Rettie AE, Trager WF, Nelson SD.

Chem Res Toxicol. 1998 Apr;11(4):295-301.

PMID:
9548799
29.

Lack of effect of azelastine and ketoconazole coadministration on electrocardiographic parameters in healthy volunteers.

Morganroth J, Lyness WH, Perhach JL, Mather GG, Harr JE, Trager WF, Levy RH, Rosenberg A.

J Clin Pharmacol. 1997 Nov;37(11):1065-72.

PMID:
9506001
30.

Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.

Koenigs LL, Peter RM, Thompson SJ, Rettie AE, Trager WF.

Drug Metab Dispos. 1997 Dec;25(12):1407-15.

PMID:
9394031
31.

Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants.

Tran A, Rey E, Pons G, Rousseau M, d'Athis P, Olive G, Mather GG, Bishop FE, Wurden CJ, Labroo R, Trager WF, Kunze KL, Thummel KE, Vincent JC, Gillardin JM, Lepage F, Levy RH.

Clin Pharmacol Ther. 1997 Nov;62(5):490-504.

PMID:
9390105
32.

Continuous culture of Plasmodium falciparum: its impact on malaria research.

Trager W, Jensen JB.

Int J Parasitol. 1997 Sep;27(9):989-1006. Review.

PMID:
9363481
33.

Genetic association between sensitivity to warfarin and expression of CYP2C9*3.

Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE.

Pharmacogenetics. 1997 Oct;7(5):361-7.

PMID:
9352571
36.

Substrate probe for the mechanism of aromatic hydroxylation catalyzed by cytochrome P450.

Darbyshire JF, Iyer KR, Grogan J, Korzekwa KR, Trager WF.

Drug Metab Dispos. 1996 Sep;24(9):1038-45.

PMID:
8886617
37.

Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.

Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, Trager WF.

Drug Metab Dispos. 1996 May;24(5):610-4.

PMID:
8723744
38.
39.

Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies.

Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, Evans JS, Bauwens JE, Trager WF.

Drug Metab Dispos. 1996 Apr;24(4):422-8.

PMID:
8801057
40.

Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies.

Kunze KL, Wienkers LC, Thummel KE, Trager WF.

Drug Metab Dispos. 1996 Apr;24(4):414-21.

PMID:
8801056
41.

Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9.

Jones JP, He M, Trager WF, Rettie AE.

Drug Metab Dispos. 1996 Jan;24(1):1-6. No abstract available.

PMID:
8825183
43.

Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites.

He M, Kunze KL, Trager WF.

Drug Metab Dispos. 1995 Jun;23(6):659-63.

PMID:
7587949
44.

Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism.

Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED.

Drug Metab Dispos. 1995 Apr;23(4):490-6.

PMID:
7600917
45.

Malaria vaccine.

Trager W.

Science. 1995 Mar 17;267(5204):1577. No abstract available.

PMID:
7886435
46.

Parasitophorous duct? Still more questions than answers.

Trager W.

Parasitol Today. 1995 Feb;11(2):69. No abstract available.

PMID:
15275378
47.

Effect of erythrocyte membrane on extracellular development of the erythrocytic cycle of Plasmodium falciparum.

Williams JH, Gill GS, Trager W.

Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):566-8.

48.

Isotope effect studies on the cytochrome P450 enzymes.

Korzekwa KR, Gillette JR, Trager WF.

Drug Metab Rev. 1995;27(1-2):45-59. Review.

PMID:
7641584
49.

Application of negative-ion chemical ionization isotope dilution gas chromatography--mass spectrometry to single-dose bioavailability studies of mefloquine.

Neal JM, Howald WN, Kunze KL, Lawrence RF, Trager WF.

J Chromatogr B Biomed Appl. 1994 Nov 18;661(2):263-9.

PMID:
7894666
50.

Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.

Hall SD, Hamman MA, Rettie AE, Wienkers LC, Trager WF, Vandenbranden M, Wrighton SA.

Drug Metab Dispos. 1994 Nov-Dec;22(6):975-8. No abstract available.

PMID:
7895619

Supplemental Content

Loading ...
Support Center